Friday 25 October 2019

Next Generation Cancer Diagnostics Market Overview | Size, Share &Future Trends | Forecast To 2028


Million Insights Market Research Released A New Research Report On Global Next Generation Cancer Diagnostics Market - Forecast Up To 2025. Report Provide Overview Of Top Key Players, Share Analysis, Size, Stake, Progress, Trends And Their Strategic Profiling In The Market, Comprehensively Analyzing Their Core Competencies, And Drawing A Competitive Landscape For The Market.

Pune, India - Next Generation Cancer Diagnostics Market size was worth USD 4,964.05 million in 2016 which is anticipated to grow at a CAGR of more than 9.7% over the forecast period. Rise in mortality rate due to the increasing occurrence of the cancer, second most predominant disease accounting for approximately 8.8 million deaths in 2015 is anticipated to escalate the market for these tests.
Advancements in tests enable early diagnosis and assist efficient detection of different types of tumors which in turn is expected to promote growth over the projected period. The introduction of new products by large bodies, merger, and acquisitions, and joint agreements such as the development of RNA-Seq Kit version by Agilent Technologies Inc. and Agendia Inc. are the factors accountable for the estimated CAGR.
Incorporation of technological advancements such as melting curve examination for identification of mutations, qPCR tools for profiling of tumor in clinical test centers, and gene deletions are accountable for the largest share apprehended by multiplexing and qPCR segment.
With the development of next-generation sequencing technology, the use of traditional methods such as protein and DNA microarrays is expected to decrease through the years. Other factors such as data interpretation tools, growth of supportive library preparation procedures, and technological advancements are accountable for the lucrative adoption of next generation oncology tests among researchers.
Cancer Type Insights
Major categorization for the types of cancer includes cervical, breast, lung, colorectal, and other tumor forms. The other types constitute leukemia, prostate, bladder, brain, skin, uterine, esophageal, Non-Hodgkin lymphoma, ovarian, liver, and thyroid.
In 2015, as per World Health Organization lung cancer was accountable for approximately 1.7 million deaths. Moreover, breast cancer incidence is also estimated to grow thereby escalating the demand for screening and diagnostic technologies.
Application Insights
Growth in the number of research schemes to develop novel products and services which enable primary detection of tumor-causing mutations is expected to affect the advancement in genetic analysis over the forecast period. Biomarker tests offer greater sensitivity in screening and also demonstrate 90% accuracy levels in investigational studies which is attributive to induce progress in the coming years.
Market Segment:

Technology Outlook (Revenue, USD Million, 2013 - 2024)
        • Next Generation Sequencing
        • qPCR & Multiplexing
        • Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        • Protein Microarrays
        • DNA Microarrays

Application Outlook (Revenue, USD Million, 2013 - 2024)
        • Biomarker Development
        • CTC Analysis
        • Proteomic Analysis
        • Epigenetic Analysis
        • Genetic Analysis

Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:
Ryan Manuel
Research Support Specialist, USA

Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria,
Model Colony, Shivaji Nagar, Pune, MH, 411016 India
tel: 91-20-65300184
Email: sales@millioninsights.com

No comments:

Post a Comment